Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). John B. Harlow appointed President and Chief Operating Officer effective September 29, 2026, adding commercial-stage biopharma leadership.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- John B. Harlow appointed President and Chief Operating Officer effective September 29, 2026, adding commercial-stage biopharma leadership
- $560,000 base salary, $35,000 signing bonus, and target annual bonus equal to 40% of salary
- Inducement equity: options for 800,000 shares plus restricted stock units covering 50,000 shares
- Option vests 25% after one year and remaining 75% monthly over 36 months, aligning retention with execution
- Severance ranges from nine months’ salary to 12 months’ salary plus target bonus after qualifying termination following a change in control
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.